Document Detail


Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
MedLine Citation:
PMID:  21105109     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Insulin sensitizers are attractive candidate therapies for nonalcoholic steatohepatitis mainly because of the strong association between this disease and insulin resistance. This review provides a critical overview of the mechanisms of action, clinical trial results, and safety issues of metformin and glitazones in nonalcoholic steatohepatitis. It also highlights methodological challenges for trial design and proposes endpoints for future proof of principle, registrational, and postmarketing trials.
Authors:
Vlad Ratziu; Stephen Caldwell; Brent A Neuschwander-Tetri
Related Documents :
18945509 - Risk of coronary artery disease associated with initial sulphonylurea treatment of pati...
17728849 - Pioglitazone hydrochloride/glimepiride.
17258489 - Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment o...
10789389 - The thiazolidinediones: a new class of antidiabetic agents.
18726829 - Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve ...
18458139 - Is the combination of sulfonylureas and metformin associated with an increased risk of ...
18024949 - Blood glucose and cerebrovascular disease in nondiabetic patients.
12021149 - The lymphocyte as a cellular model to study insights into the pathophysiology of diabet...
2337999 - Transient hyperglycemia during abdominal aortic surgery.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  52     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-24     Completed Date:  2011-01-10     Revised Date:  2011-05-20    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2206-15     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 American Association for the Study of Liver Diseases.
Affiliation:
Université Pierre et Marie Curie, Assistance Publique Hôpitaux de Paris, Hôpital Pitié Salpêtrière, INSERM UMRS 893 Paris, France. vratziu@teaser.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Fatty Liver / diet therapy,  drug therapy*
Humans
Hypoglycemic Agents / therapeutic use*
Insulin / therapeutic use*
Insulin Resistance / physiology
Metformin / adverse effects,  therapeutic use*
Thiazolidinediones / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Thiazolidinediones; 11061-68-0/Insulin; 657-24-9/Metformin
Comments/Corrections
Comment In:
Hepatology. 2011 Apr;53(4):1404-5; author reply 1405   [PMID:  21480350 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhos...
Next Document:  Sunitinib rechallenge in metastatic renal cell carcinoma patients.